nodes	percent_of_prediction	percent_of_DWPC	metapath
Fesoterodine—ABCB1—Mitomycin—urinary bladder cancer	0.202	0.361	CbGbCtD
Fesoterodine—CYP3A4—Thiotepa—urinary bladder cancer	0.0919	0.164	CbGbCtD
Fesoterodine—ABCB1—Gemcitabine—urinary bladder cancer	0.0582	0.104	CbGbCtD
Fesoterodine—ABCB1—Cisplatin—urinary bladder cancer	0.0423	0.0755	CbGbCtD
Fesoterodine—ABCB1—Etoposide—urinary bladder cancer	0.0416	0.0741	CbGbCtD
Fesoterodine—CHRM3—ureter—urinary bladder cancer	0.039	0.295	CbGeAlD
Fesoterodine—ABCB1—Doxorubicin—urinary bladder cancer	0.0284	0.0506	CbGbCtD
Fesoterodine—CHRM3—muscle of abdomen—urinary bladder cancer	0.0281	0.212	CbGeAlD
Fesoterodine—ABCB1—Methotrexate—urinary bladder cancer	0.0275	0.049	CbGbCtD
Fesoterodine—CYP2D6—Doxorubicin—urinary bladder cancer	0.0267	0.0477	CbGbCtD
Fesoterodine—CYP3A4—Etoposide—urinary bladder cancer	0.0249	0.0444	CbGbCtD
Fesoterodine—CYP3A4—Doxorubicin—urinary bladder cancer	0.017	0.0303	CbGbCtD
Fesoterodine—CYP3A4—urine—urinary bladder cancer	0.00696	0.0527	CbGeAlD
Fesoterodine—CYP2D6—urine—urinary bladder cancer	0.00685	0.0518	CbGeAlD
Fesoterodine—CHRM5—epithelium—urinary bladder cancer	0.00598	0.0452	CbGeAlD
Fesoterodine—CHRM2—prostate gland—urinary bladder cancer	0.00558	0.0423	CbGeAlD
Fesoterodine—CHRM1—prostate gland—urinary bladder cancer	0.00508	0.0385	CbGeAlD
Fesoterodine—CHRM3—prostate gland—urinary bladder cancer	0.00455	0.0344	CbGeAlD
Fesoterodine—CHRM3—smooth muscle tissue—urinary bladder cancer	0.00322	0.0244	CbGeAlD
Fesoterodine—CHRM3—renal system—urinary bladder cancer	0.0031	0.0235	CbGeAlD
Fesoterodine—CHRM3—urethra—urinary bladder cancer	0.00305	0.023	CbGeAlD
Fesoterodine—CHRM1—female reproductive system—urinary bladder cancer	0.00277	0.021	CbGeAlD
Fesoterodine—CHRM3—female reproductive system—urinary bladder cancer	0.00248	0.0188	CbGeAlD
Fesoterodine—ABCB1—prostate gland—urinary bladder cancer	0.00177	0.0134	CbGeAlD
Fesoterodine—CYP3A4—renal system—urinary bladder cancer	0.0017	0.0129	CbGeAlD
Fesoterodine—CYP2D6—renal system—urinary bladder cancer	0.00168	0.0127	CbGeAlD
Fesoterodine—ABCB1—seminal vesicle—urinary bladder cancer	0.0015	0.0113	CbGeAlD
Fesoterodine—CYP3A4—female reproductive system—urinary bladder cancer	0.00136	0.0103	CbGeAlD
Fesoterodine—CYP2D6—female reproductive system—urinary bladder cancer	0.00134	0.0102	CbGeAlD
Fesoterodine—ABCB1—epithelium—urinary bladder cancer	0.0013	0.00984	CbGeAlD
Fesoterodine—ABCB1—renal system—urinary bladder cancer	0.00121	0.00913	CbGeAlD
Fesoterodine—ABCB1—urethra—urinary bladder cancer	0.00118	0.00896	CbGeAlD
Fesoterodine—ABCB1—female reproductive system—urinary bladder cancer	0.000966	0.00731	CbGeAlD
Fesoterodine—Tachycardia—Thiotepa—urinary bladder cancer	0.000891	0.00297	CcSEcCtD
Fesoterodine—Skin disorder—Thiotepa—urinary bladder cancer	0.000887	0.00296	CcSEcCtD
Fesoterodine—Dry eye—Doxorubicin—urinary bladder cancer	0.000881	0.00293	CcSEcCtD
Fesoterodine—ABCB1—vagina—urinary bladder cancer	0.000873	0.00661	CbGeAlD
Fesoterodine—Vision blurred—Fluorouracil—urinary bladder cancer	0.000872	0.00291	CcSEcCtD
Fesoterodine—Flatulence—Cisplatin—urinary bladder cancer	0.000864	0.00288	CcSEcCtD
Fesoterodine—Eye disorder—Etoposide—urinary bladder cancer	0.000863	0.00288	CcSEcCtD
Fesoterodine—Cardiac disorder—Etoposide—urinary bladder cancer	0.000857	0.00286	CcSEcCtD
Fesoterodine—Mediastinal disorder—Etoposide—urinary bladder cancer	0.000832	0.00277	CcSEcCtD
Fesoterodine—Vision blurred—Cisplatin—urinary bladder cancer	0.000827	0.00275	CcSEcCtD
Fesoterodine—Cough—Gemcitabine—urinary bladder cancer	0.000821	0.00274	CcSEcCtD
Fesoterodine—Somnolence—Thiotepa—urinary bladder cancer	0.000812	0.00271	CcSEcCtD
Fesoterodine—Dyspepsia—Thiotepa—urinary bladder cancer	0.000804	0.00268	CcSEcCtD
Fesoterodine—Chest pain—Gemcitabine—urinary bladder cancer	0.000801	0.00267	CcSEcCtD
Fesoterodine—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.000796	0.00265	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000788	0.00263	CcSEcCtD
Fesoterodine—Chest pain—Fluorouracil—urinary bladder cancer	0.000788	0.00263	CcSEcCtD
Fesoterodine—Fatigue—Thiotepa—urinary bladder cancer	0.000787	0.00262	CcSEcCtD
Fesoterodine—Dysgeusia—Etoposide—urinary bladder cancer	0.000787	0.00262	CcSEcCtD
Fesoterodine—Constipation—Thiotepa—urinary bladder cancer	0.000781	0.0026	CcSEcCtD
Fesoterodine—Back pain—Etoposide—urinary bladder cancer	0.000777	0.00259	CcSEcCtD
Fesoterodine—Infection—Gemcitabine—urinary bladder cancer	0.000763	0.00254	CcSEcCtD
Fesoterodine—Confusional state—Fluorouracil—urinary bladder cancer	0.000761	0.00254	CcSEcCtD
Fesoterodine—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.000753	0.00251	CcSEcCtD
Fesoterodine—Feeling abnormal—Thiotepa—urinary bladder cancer	0.000752	0.00251	CcSEcCtD
Fesoterodine—Infection—Fluorouracil—urinary bladder cancer	0.00075	0.0025	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.000747	0.00249	CcSEcCtD
Fesoterodine—Skin disorder—Gemcitabine—urinary bladder cancer	0.000746	0.00249	CcSEcCtD
Fesoterodine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.000742	0.00247	CcSEcCtD
Fesoterodine—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.000741	0.00247	CcSEcCtD
Fesoterodine—Tachycardia—Fluorouracil—urinary bladder cancer	0.000737	0.00246	CcSEcCtD
Fesoterodine—Urticaria—Thiotepa—urinary bladder cancer	0.000725	0.00242	CcSEcCtD
Fesoterodine—Face oedema—Epirubicin—urinary bladder cancer	0.000722	0.00241	CcSEcCtD
Fesoterodine—Vertigo—Etoposide—urinary bladder cancer	0.000722	0.00241	CcSEcCtD
Fesoterodine—Abdominal pain—Thiotepa—urinary bladder cancer	0.000722	0.00241	CcSEcCtD
Fesoterodine—Infection—Cisplatin—urinary bladder cancer	0.000711	0.00237	CcSEcCtD
Fesoterodine—Nervous system disorder—Cisplatin—urinary bladder cancer	0.000702	0.00234	CcSEcCtD
Fesoterodine—Cough—Etoposide—urinary bladder cancer	0.000701	0.00234	CcSEcCtD
Fesoterodine—Tachycardia—Cisplatin—urinary bladder cancer	0.000699	0.00233	CcSEcCtD
Fesoterodine—Skin disorder—Cisplatin—urinary bladder cancer	0.000695	0.00232	CcSEcCtD
Fesoterodine—Insomnia—Gemcitabine—urinary bladder cancer	0.000695	0.00232	CcSEcCtD
Fesoterodine—Dry skin—Epirubicin—urinary bladder cancer	0.000686	0.00228	CcSEcCtD
Fesoterodine—Chest pain—Etoposide—urinary bladder cancer	0.000684	0.00228	CcSEcCtD
Fesoterodine—Abdominal pain upper—Epirubicin—urinary bladder cancer	0.000683	0.00228	CcSEcCtD
Fesoterodine—Insomnia—Fluorouracil—urinary bladder cancer	0.000683	0.00228	CcSEcCtD
Fesoterodine—Somnolence—Gemcitabine—urinary bladder cancer	0.000683	0.00228	CcSEcCtD
Fesoterodine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000679	0.00226	CcSEcCtD
Fesoterodine—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000673	0.00224	CcSEcCtD
Fesoterodine—Somnolence—Fluorouracil—urinary bladder cancer	0.000671	0.00224	CcSEcCtD
Fesoterodine—Face oedema—Doxorubicin—urinary bladder cancer	0.000668	0.00223	CcSEcCtD
Fesoterodine—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000665	0.00222	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000663	0.00221	CcSEcCtD
Fesoterodine—Abdominal discomfort—Methotrexate—urinary bladder cancer	0.000662	0.00221	CcSEcCtD
Fesoterodine—Fatigue—Gemcitabine—urinary bladder cancer	0.000662	0.00221	CcSEcCtD
Fesoterodine—Confusional state—Etoposide—urinary bladder cancer	0.000661	0.0022	CcSEcCtD
Fesoterodine—Alanine aminotransferase increased—Epirubicin—urinary bladder cancer	0.00066	0.0022	CcSEcCtD
Fesoterodine—Constipation—Gemcitabine—urinary bladder cancer	0.000657	0.00219	CcSEcCtD
Fesoterodine—Asthenia—Thiotepa—urinary bladder cancer	0.000655	0.00218	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000652	0.00217	CcSEcCtD
Fesoterodine—Infection—Etoposide—urinary bladder cancer	0.000652	0.00217	CcSEcCtD
Fesoterodine—Dysuria—Methotrexate—urinary bladder cancer	0.000646	0.00215	CcSEcCtD
Fesoterodine—Pruritus—Thiotepa—urinary bladder cancer	0.000646	0.00215	CcSEcCtD
Fesoterodine—Upper respiratory tract infection—Methotrexate—urinary bladder cancer	0.000642	0.00214	CcSEcCtD
Fesoterodine—Tachycardia—Etoposide—urinary bladder cancer	0.00064	0.00213	CcSEcCtD
Fesoterodine—Skin disorder—Etoposide—urinary bladder cancer	0.000637	0.00212	CcSEcCtD
Fesoterodine—Dry skin—Doxorubicin—urinary bladder cancer	0.000634	0.00211	CcSEcCtD
Fesoterodine—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000633	0.00211	CcSEcCtD
Fesoterodine—Abdominal pain upper—Doxorubicin—urinary bladder cancer	0.000632	0.00211	CcSEcCtD
Fesoterodine—Angina pectoris—Epirubicin—urinary bladder cancer	0.00063	0.0021	CcSEcCtD
Fesoterodine—Diarrhoea—Thiotepa—urinary bladder cancer	0.000625	0.00208	CcSEcCtD
Fesoterodine—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000622	0.00207	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000618	0.00206	CcSEcCtD
Fesoterodine—Infestation NOS—Methotrexate—urinary bladder cancer	0.000616	0.00205	CcSEcCtD
Fesoterodine—Infestation—Methotrexate—urinary bladder cancer	0.000616	0.00205	CcSEcCtD
Fesoterodine—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	0.00061	0.00203	CcSEcCtD
Fesoterodine—Dysuria—Epirubicin—urinary bladder cancer	0.000605	0.00201	CcSEcCtD
Fesoterodine—Dizziness—Thiotepa—urinary bladder cancer	0.000604	0.00201	CcSEcCtD
Fesoterodine—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.000601	0.002	CcSEcCtD
Fesoterodine—Urticaria—Fluorouracil—urinary bladder cancer	0.0006	0.002	CcSEcCtD
Fesoterodine—Feeling abnormal—Cisplatin—urinary bladder cancer	0.00059	0.00197	CcSEcCtD
Fesoterodine—Somnolence—Etoposide—urinary bladder cancer	0.000583	0.00194	CcSEcCtD
Fesoterodine—Angina pectoris—Doxorubicin—urinary bladder cancer	0.000583	0.00194	CcSEcCtD
Fesoterodine—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000583	0.00194	CcSEcCtD
Fesoterodine—Infestation NOS—Epirubicin—urinary bladder cancer	0.000576	0.00192	CcSEcCtD
Fesoterodine—Infestation—Epirubicin—urinary bladder cancer	0.000576	0.00192	CcSEcCtD
Fesoterodine—Rash—Thiotepa—urinary bladder cancer	0.000576	0.00192	CcSEcCtD
Fesoterodine—Dermatitis—Thiotepa—urinary bladder cancer	0.000575	0.00192	CcSEcCtD
Fesoterodine—Headache—Thiotepa—urinary bladder cancer	0.000572	0.00191	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000566	0.00189	CcSEcCtD
Fesoterodine—Fatigue—Etoposide—urinary bladder cancer	0.000565	0.00188	CcSEcCtD
Fesoterodine—ABCB1—lymph node—urinary bladder cancer	0.000565	0.00428	CbGeAlD
Fesoterodine—Constipation—Etoposide—urinary bladder cancer	0.000561	0.00187	CcSEcCtD
Fesoterodine—Urinary tract infection—Epirubicin—urinary bladder cancer	0.00056	0.00187	CcSEcCtD
Fesoterodine—Dysuria—Doxorubicin—urinary bladder cancer	0.000559	0.00186	CcSEcCtD
Fesoterodine—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000556	0.00185	CcSEcCtD
Fesoterodine—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000556	0.00185	CcSEcCtD
Fesoterodine—Asthenia—Gemcitabine—urinary bladder cancer	0.000551	0.00184	CcSEcCtD
Fesoterodine—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000546	0.00182	CcSEcCtD
Fesoterodine—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000545	0.00182	CcSEcCtD
Fesoterodine—Pruritus—Gemcitabine—urinary bladder cancer	0.000543	0.00181	CcSEcCtD
Fesoterodine—Nausea—Thiotepa—urinary bladder cancer	0.000542	0.00181	CcSEcCtD
Fesoterodine—Urethral disorder—Methotrexate—urinary bladder cancer	0.000542	0.00181	CcSEcCtD
Fesoterodine—Feeling abnormal—Etoposide—urinary bladder cancer	0.00054	0.0018	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000536	0.00179	CcSEcCtD
Fesoterodine—Pruritus—Fluorouracil—urinary bladder cancer	0.000534	0.00178	CcSEcCtD
Fesoterodine—Infestation—Doxorubicin—urinary bladder cancer	0.000533	0.00178	CcSEcCtD
Fesoterodine—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000533	0.00178	CcSEcCtD
Fesoterodine—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000527	0.00176	CcSEcCtD
Fesoterodine—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000525	0.00175	CcSEcCtD
Fesoterodine—Urticaria—Etoposide—urinary bladder cancer	0.000521	0.00174	CcSEcCtD
Fesoterodine—Abdominal pain—Etoposide—urinary bladder cancer	0.000518	0.00173	CcSEcCtD
Fesoterodine—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000518	0.00173	CcSEcCtD
Fesoterodine—Eye disorder—Methotrexate—urinary bladder cancer	0.000517	0.00172	CcSEcCtD
Fesoterodine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000517	0.00172	CcSEcCtD
Fesoterodine—Asthenia—Cisplatin—urinary bladder cancer	0.000514	0.00171	CcSEcCtD
Fesoterodine—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000513	0.00171	CcSEcCtD
Fesoterodine—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000511	0.0017	CcSEcCtD
Fesoterodine—Oedema peripheral—Epirubicin—urinary bladder cancer	0.00051	0.0017	CcSEcCtD
Fesoterodine—Urethral disorder—Epirubicin—urinary bladder cancer	0.000507	0.00169	CcSEcCtD
Fesoterodine—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000504	0.00168	CcSEcCtD
Fesoterodine—Dizziness—Fluorouracil—urinary bladder cancer	0.000499	0.00166	CcSEcCtD
Fesoterodine—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000498	0.00166	CcSEcCtD
Fesoterodine—Diarrhoea—Cisplatin—urinary bladder cancer	0.00049	0.00163	CcSEcCtD
Fesoterodine—Mental disorder—Methotrexate—urinary bladder cancer	0.000484	0.00161	CcSEcCtD
Fesoterodine—Rash—Gemcitabine—urinary bladder cancer	0.000484	0.00161	CcSEcCtD
Fesoterodine—Dermatitis—Gemcitabine—urinary bladder cancer	0.000484	0.00161	CcSEcCtD
Fesoterodine—Eye disorder—Epirubicin—urinary bladder cancer	0.000484	0.00161	CcSEcCtD
Fesoterodine—Hypersensitivity—Etoposide—urinary bladder cancer	0.000483	0.00161	CcSEcCtD
Fesoterodine—Headache—Gemcitabine—urinary bladder cancer	0.000481	0.0016	CcSEcCtD
Fesoterodine—Cardiac disorder—Epirubicin—urinary bladder cancer	0.00048	0.0016	CcSEcCtD
Fesoterodine—Rash—Fluorouracil—urinary bladder cancer	0.000476	0.00159	CcSEcCtD
Fesoterodine—Dermatitis—Fluorouracil—urinary bladder cancer	0.000476	0.00159	CcSEcCtD
Fesoterodine—Headache—Fluorouracil—urinary bladder cancer	0.000473	0.00158	CcSEcCtD
Fesoterodine—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000473	0.00158	CcSEcCtD
Fesoterodine—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000472	0.00157	CcSEcCtD
Fesoterodine—Dysgeusia—Methotrexate—urinary bladder cancer	0.000471	0.00157	CcSEcCtD
Fesoterodine—Asthenia—Etoposide—urinary bladder cancer	0.000471	0.00157	CcSEcCtD
Fesoterodine—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000469	0.00156	CcSEcCtD
Fesoterodine—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000466	0.00155	CcSEcCtD
Fesoterodine—Back pain—Methotrexate—urinary bladder cancer	0.000466	0.00155	CcSEcCtD
Fesoterodine—Pruritus—Etoposide—urinary bladder cancer	0.000464	0.00155	CcSEcCtD
Fesoterodine—Nausea—Gemcitabine—urinary bladder cancer	0.000456	0.00152	CcSEcCtD
Fesoterodine—Vision blurred—Methotrexate—urinary bladder cancer	0.000454	0.00151	CcSEcCtD
Fesoterodine—Mental disorder—Epirubicin—urinary bladder cancer	0.000453	0.00151	CcSEcCtD
Fesoterodine—Rash—Cisplatin—urinary bladder cancer	0.000451	0.0015	CcSEcCtD
Fesoterodine—Dermatitis—Cisplatin—urinary bladder cancer	0.000451	0.0015	CcSEcCtD
Fesoterodine—Diarrhoea—Etoposide—urinary bladder cancer	0.000449	0.0015	CcSEcCtD
Fesoterodine—Nausea—Fluorouracil—urinary bladder cancer	0.000449	0.00149	CcSEcCtD
Fesoterodine—Eye disorder—Doxorubicin—urinary bladder cancer	0.000447	0.00149	CcSEcCtD
Fesoterodine—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000444	0.00148	CcSEcCtD
Fesoterodine—Flatulence—Epirubicin—urinary bladder cancer	0.000444	0.00148	CcSEcCtD
Fesoterodine—Dysgeusia—Epirubicin—urinary bladder cancer	0.000441	0.00147	CcSEcCtD
Fesoterodine—Back pain—Epirubicin—urinary bladder cancer	0.000436	0.00145	CcSEcCtD
Fesoterodine—Dizziness—Etoposide—urinary bladder cancer	0.000434	0.00145	CcSEcCtD
Fesoterodine—Vertigo—Methotrexate—urinary bladder cancer	0.000432	0.00144	CcSEcCtD
Fesoterodine—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000431	0.00144	CcSEcCtD
Fesoterodine—Nausea—Cisplatin—urinary bladder cancer	0.000425	0.00142	CcSEcCtD
Fesoterodine—Vision blurred—Epirubicin—urinary bladder cancer	0.000425	0.00141	CcSEcCtD
Fesoterodine—Cough—Methotrexate—urinary bladder cancer	0.00042	0.0014	CcSEcCtD
Fesoterodine—Mental disorder—Doxorubicin—urinary bladder cancer	0.000419	0.0014	CcSEcCtD
Fesoterodine—Rash—Etoposide—urinary bladder cancer	0.000414	0.00138	CcSEcCtD
Fesoterodine—Dermatitis—Etoposide—urinary bladder cancer	0.000413	0.00138	CcSEcCtD
Fesoterodine—Headache—Etoposide—urinary bladder cancer	0.000411	0.00137	CcSEcCtD
Fesoterodine—Flatulence—Doxorubicin—urinary bladder cancer	0.000411	0.00137	CcSEcCtD
Fesoterodine—Chest pain—Methotrexate—urinary bladder cancer	0.00041	0.00137	CcSEcCtD
Fesoterodine—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000408	0.00136	CcSEcCtD
Fesoterodine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000407	0.00136	CcSEcCtD
Fesoterodine—Vertigo—Epirubicin—urinary bladder cancer	0.000405	0.00135	CcSEcCtD
Fesoterodine—Back pain—Doxorubicin—urinary bladder cancer	0.000403	0.00134	CcSEcCtD
Fesoterodine—Palpitations—Epirubicin—urinary bladder cancer	0.000398	0.00133	CcSEcCtD
Fesoterodine—Confusional state—Methotrexate—urinary bladder cancer	0.000396	0.00132	CcSEcCtD
Fesoterodine—Cough—Epirubicin—urinary bladder cancer	0.000393	0.00131	CcSEcCtD
Fesoterodine—Vision blurred—Doxorubicin—urinary bladder cancer	0.000393	0.00131	CcSEcCtD
Fesoterodine—Infection—Methotrexate—urinary bladder cancer	0.00039	0.0013	CcSEcCtD
Fesoterodine—Nausea—Etoposide—urinary bladder cancer	0.00039	0.0013	CcSEcCtD
Fesoterodine—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000385	0.00128	CcSEcCtD
Fesoterodine—Chest pain—Epirubicin—urinary bladder cancer	0.000383	0.00128	CcSEcCtD
Fesoterodine—Skin disorder—Methotrexate—urinary bladder cancer	0.000382	0.00127	CcSEcCtD
Fesoterodine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000381	0.00127	CcSEcCtD
Fesoterodine—Dry mouth—Epirubicin—urinary bladder cancer	0.000375	0.00125	CcSEcCtD
Fesoterodine—Vertigo—Doxorubicin—urinary bladder cancer	0.000374	0.00125	CcSEcCtD
Fesoterodine—Confusional state—Epirubicin—urinary bladder cancer	0.000371	0.00124	CcSEcCtD
Fesoterodine—Palpitations—Doxorubicin—urinary bladder cancer	0.000368	0.00123	CcSEcCtD
Fesoterodine—Infection—Epirubicin—urinary bladder cancer	0.000365	0.00122	CcSEcCtD
Fesoterodine—Cough—Doxorubicin—urinary bladder cancer	0.000364	0.00121	CcSEcCtD
Fesoterodine—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000361	0.0012	CcSEcCtD
Fesoterodine—Tachycardia—Epirubicin—urinary bladder cancer	0.000359	0.0012	CcSEcCtD
Fesoterodine—Skin disorder—Epirubicin—urinary bladder cancer	0.000357	0.00119	CcSEcCtD
Fesoterodine—Insomnia—Methotrexate—urinary bladder cancer	0.000355	0.00118	CcSEcCtD
Fesoterodine—Chest pain—Doxorubicin—urinary bladder cancer	0.000355	0.00118	CcSEcCtD
Fesoterodine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000352	0.00117	CcSEcCtD
Fesoterodine—Somnolence—Methotrexate—urinary bladder cancer	0.000349	0.00116	CcSEcCtD
Fesoterodine—Dry mouth—Doxorubicin—urinary bladder cancer	0.000347	0.00116	CcSEcCtD
Fesoterodine—Dyspepsia—Methotrexate—urinary bladder cancer	0.000346	0.00115	CcSEcCtD
Fesoterodine—Confusional state—Doxorubicin—urinary bladder cancer	0.000343	0.00114	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000339	0.00113	CcSEcCtD
Fesoterodine—Fatigue—Methotrexate—urinary bladder cancer	0.000339	0.00113	CcSEcCtD
Fesoterodine—Infection—Doxorubicin—urinary bladder cancer	0.000338	0.00113	CcSEcCtD
Fesoterodine—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000334	0.00111	CcSEcCtD
Fesoterodine—Insomnia—Epirubicin—urinary bladder cancer	0.000333	0.00111	CcSEcCtD
Fesoterodine—Tachycardia—Doxorubicin—urinary bladder cancer	0.000332	0.00111	CcSEcCtD
Fesoterodine—Skin disorder—Doxorubicin—urinary bladder cancer	0.00033	0.0011	CcSEcCtD
Fesoterodine—Somnolence—Epirubicin—urinary bladder cancer	0.000327	0.00109	CcSEcCtD
Fesoterodine—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000324	0.00108	CcSEcCtD
Fesoterodine—Dyspepsia—Epirubicin—urinary bladder cancer	0.000324	0.00108	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000321	0.00107	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000317	0.00106	CcSEcCtD
Fesoterodine—Fatigue—Epirubicin—urinary bladder cancer	0.000317	0.00106	CcSEcCtD
Fesoterodine—Constipation—Epirubicin—urinary bladder cancer	0.000314	0.00105	CcSEcCtD
Fesoterodine—Urticaria—Methotrexate—urinary bladder cancer	0.000312	0.00104	CcSEcCtD
Fesoterodine—Abdominal pain—Methotrexate—urinary bladder cancer	0.000311	0.00103	CcSEcCtD
Fesoterodine—Insomnia—Doxorubicin—urinary bladder cancer	0.000308	0.00103	CcSEcCtD
Fesoterodine—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000303	0.00101	CcSEcCtD
Fesoterodine—Somnolence—Doxorubicin—urinary bladder cancer	0.000302	0.00101	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000301	0.001	CcSEcCtD
Fesoterodine—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000299	0.000998	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000294	0.000979	CcSEcCtD
Fesoterodine—Fatigue—Doxorubicin—urinary bladder cancer	0.000293	0.000977	CcSEcCtD
Fesoterodine—Urticaria—Epirubicin—urinary bladder cancer	0.000292	0.000973	CcSEcCtD
Fesoterodine—Constipation—Doxorubicin—urinary bladder cancer	0.000291	0.000969	CcSEcCtD
Fesoterodine—Abdominal pain—Epirubicin—urinary bladder cancer	0.000291	0.000969	CcSEcCtD
Fesoterodine—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000289	0.000965	CcSEcCtD
Fesoterodine—Asthenia—Methotrexate—urinary bladder cancer	0.000282	0.000939	CcSEcCtD
Fesoterodine—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.00028	0.000934	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000278	0.000927	CcSEcCtD
Fesoterodine—Pruritus—Methotrexate—urinary bladder cancer	0.000278	0.000926	CcSEcCtD
Fesoterodine—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000271	0.000903	CcSEcCtD
Fesoterodine—Urticaria—Doxorubicin—urinary bladder cancer	0.00027	0.000901	CcSEcCtD
Fesoterodine—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000269	0.000896	CcSEcCtD
Fesoterodine—Diarrhoea—Methotrexate—urinary bladder cancer	0.000269	0.000896	CcSEcCtD
Fesoterodine—Asthenia—Epirubicin—urinary bladder cancer	0.000264	0.000879	CcSEcCtD
Fesoterodine—Pruritus—Epirubicin—urinary bladder cancer	0.00026	0.000867	CcSEcCtD
Fesoterodine—Dizziness—Methotrexate—urinary bladder cancer	0.00026	0.000866	CcSEcCtD
Fesoterodine—Diarrhoea—Epirubicin—urinary bladder cancer	0.000252	0.000838	CcSEcCtD
Fesoterodine—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000251	0.000835	CcSEcCtD
Fesoterodine—Rash—Methotrexate—urinary bladder cancer	0.000248	0.000825	CcSEcCtD
Fesoterodine—Dermatitis—Methotrexate—urinary bladder cancer	0.000247	0.000825	CcSEcCtD
Fesoterodine—Headache—Methotrexate—urinary bladder cancer	0.000246	0.00082	CcSEcCtD
Fesoterodine—Asthenia—Doxorubicin—urinary bladder cancer	0.000244	0.000813	CcSEcCtD
Fesoterodine—Dizziness—Epirubicin—urinary bladder cancer	0.000243	0.00081	CcSEcCtD
Fesoterodine—Pruritus—Doxorubicin—urinary bladder cancer	0.000241	0.000802	CcSEcCtD
Fesoterodine—Nausea—Methotrexate—urinary bladder cancer	0.000233	0.000778	CcSEcCtD
Fesoterodine—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000233	0.000776	CcSEcCtD
Fesoterodine—Rash—Epirubicin—urinary bladder cancer	0.000232	0.000772	CcSEcCtD
Fesoterodine—Dermatitis—Epirubicin—urinary bladder cancer	0.000232	0.000772	CcSEcCtD
Fesoterodine—Headache—Epirubicin—urinary bladder cancer	0.00023	0.000768	CcSEcCtD
Fesoterodine—Dizziness—Doxorubicin—urinary bladder cancer	0.000225	0.00075	CcSEcCtD
Fesoterodine—Nausea—Epirubicin—urinary bladder cancer	0.000218	0.000728	CcSEcCtD
Fesoterodine—Rash—Doxorubicin—urinary bladder cancer	0.000214	0.000715	CcSEcCtD
Fesoterodine—Dermatitis—Doxorubicin—urinary bladder cancer	0.000214	0.000714	CcSEcCtD
Fesoterodine—Headache—Doxorubicin—urinary bladder cancer	0.000213	0.00071	CcSEcCtD
Fesoterodine—Nausea—Doxorubicin—urinary bladder cancer	0.000202	0.000673	CcSEcCtD
Fesoterodine—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	5.6e-06	0.000798	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR ligand binding—CXCL8—urinary bladder cancer	5.56e-06	0.000793	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR ligand binding—CXCL8—urinary bladder cancer	5.55e-06	0.00079	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR ligand binding—CXCL8—urinary bladder cancer	5.49e-06	0.000783	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	5.31e-06	0.000757	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—NAT1—urinary bladder cancer	5.31e-06	0.000757	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR downstream signaling—RHOA—urinary bladder cancer	5.31e-06	0.000757	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—TYMP—urinary bladder cancer	5.22e-06	0.000744	CbGpPWpGaD
Fesoterodine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	5.13e-06	0.00073	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—S100B—urinary bladder cancer	5.09e-06	0.000725	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR downstream signaling—RHOA—urinary bladder cancer	5.09e-06	0.000725	CbGpPWpGaD
Fesoterodine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	5.01e-06	0.000714	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—TYMP—urinary bladder cancer	4.92e-06	0.000701	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—S100B—urinary bladder cancer	4.87e-06	0.000694	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	4.86e-06	0.000692	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—RHOA—urinary bladder cancer	4.82e-06	0.000687	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—NQO1—urinary bladder cancer	4.8e-06	0.000684	CbGpPWpGaD
Fesoterodine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	4.78e-06	0.00068	CbGpPWpGaD
Fesoterodine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	4.74e-06	0.000675	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—RBX1—urinary bladder cancer	4.73e-06	0.000674	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—NAT2—urinary bladder cancer	4.72e-06	0.000673	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—RBX1—urinary bladder cancer	4.72e-06	0.000672	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—RBX1—urinary bladder cancer	4.67e-06	0.000666	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR downstream signaling—CXCL8—urinary bladder cancer	4.66e-06	0.000664	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—RHOA—urinary bladder cancer	4.62e-06	0.000658	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—NCOR1—urinary bladder cancer	4.58e-06	0.000652	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR downstream signaling—CXCL8—urinary bladder cancer	4.47e-06	0.000636	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR downstream signaling—IL2—urinary bladder cancer	4.46e-06	0.000635	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—NAT2—urinary bladder cancer	4.45e-06	0.000634	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—TSC1—urinary bladder cancer	4.45e-06	0.000634	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—TSC1—urinary bladder cancer	4.44e-06	0.000632	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—TSC1—urinary bladder cancer	4.39e-06	0.000626	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—NCOR1—urinary bladder cancer	4.38e-06	0.000624	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	4.38e-06	0.000623	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR downstream signaling—IL2—urinary bladder cancer	4.27e-06	0.000608	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—JAG1—urinary bladder cancer	4.24e-06	0.000604	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—CXCL8—urinary bladder cancer	4.23e-06	0.000603	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—JAG1—urinary bladder cancer	4.22e-06	0.000602	CbGpPWpGaD
Fesoterodine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	4.21e-06	0.0006	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—JAG1—urinary bladder cancer	4.18e-06	0.000596	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	4.13e-06	0.000589	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—RRM2—urinary bladder cancer	4.08e-06	0.000581	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—CXCL8—urinary bladder cancer	4.06e-06	0.000578	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—IL2—urinary bladder cancer	4.05e-06	0.000577	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—TERT—urinary bladder cancer	4.03e-06	0.000574	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	4.03e-06	0.000574	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—GSTP1—urinary bladder cancer	4e-06	0.00057	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—IL2—urinary bladder cancer	3.88e-06	0.000552	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—TERT—urinary bladder cancer	3.86e-06	0.00055	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—RRM2—urinary bladder cancer	3.84e-06	0.000548	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—HPGDS—urinary bladder cancer	3.78e-06	0.000538	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—ENO2—urinary bladder cancer	3.78e-06	0.000538	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—TYMS—urinary bladder cancer	3.72e-06	0.00053	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—FGFR3—urinary bladder cancer	3.7e-06	0.000527	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—GSTM1—urinary bladder cancer	3.68e-06	0.000524	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—NCOR1—urinary bladder cancer	3.68e-06	0.000524	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—GSTT1—urinary bladder cancer	3.66e-06	0.000522	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—ESR1—urinary bladder cancer	3.59e-06	0.000512	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR downstream signaling—RHOA—urinary bladder cancer	3.58e-06	0.00051	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR downstream signaling—RHOA—urinary bladder cancer	3.57e-06	0.000509	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	3.56e-06	0.000507	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—ENO2—urinary bladder cancer	3.56e-06	0.000507	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—FGFR3—urinary bladder cancer	3.54e-06	0.000505	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR downstream signaling—RHOA—urinary bladder cancer	3.54e-06	0.000504	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—GPX1—urinary bladder cancer	3.52e-06	0.000502	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—ERCC2—urinary bladder cancer	3.46e-06	0.000493	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	3.45e-06	0.000492	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—ESR1—urinary bladder cancer	3.44e-06	0.00049	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—S100B—urinary bladder cancer	3.43e-06	0.000489	CbGpPWpGaD
Fesoterodine—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	3.43e-06	0.000489	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—S100B—urinary bladder cancer	3.42e-06	0.000487	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—S100B—urinary bladder cancer	3.39e-06	0.000483	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—RHOA—urinary bladder cancer	3.25e-06	0.000463	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—MTHFR—urinary bladder cancer	3.25e-06	0.000463	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—RHOA—urinary bladder cancer	3.24e-06	0.000462	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—TYMP—urinary bladder cancer	3.22e-06	0.000459	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—RHOA—urinary bladder cancer	3.21e-06	0.000457	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—CREBBP—urinary bladder cancer	3.15e-06	0.000449	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR downstream signaling—CXCL8—urinary bladder cancer	3.14e-06	0.000448	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR downstream signaling—CXCL8—urinary bladder cancer	3.13e-06	0.000447	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—IGF1—urinary bladder cancer	3.11e-06	0.000443	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR downstream signaling—CXCL8—urinary bladder cancer	3.1e-06	0.000442	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—EGFR—urinary bladder cancer	3.1e-06	0.000441	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—NCOR1—urinary bladder cancer	3.09e-06	0.00044	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—NCOR1—urinary bladder cancer	3.08e-06	0.000438	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—NCOR1—urinary bladder cancer	3.05e-06	0.000434	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—NQO1—urinary bladder cancer	3.04e-06	0.000434	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—CREBBP—urinary bladder cancer	3.02e-06	0.00043	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR downstream signaling—IL2—urinary bladder cancer	3.01e-06	0.000428	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR downstream signaling—IL2—urinary bladder cancer	3e-06	0.000427	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—IGF1—urinary bladder cancer	2.98e-06	0.000424	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR downstream signaling—IL2—urinary bladder cancer	2.97e-06	0.000423	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—EGFR—urinary bladder cancer	2.96e-06	0.000422	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—KRAS—urinary bladder cancer	2.92e-06	0.000417	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—NAT2—urinary bladder cancer	2.91e-06	0.000415	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—NQO1—urinary bladder cancer	2.87e-06	0.000409	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—CXCL8—urinary bladder cancer	2.86e-06	0.000407	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—RHOA—urinary bladder cancer	2.85e-06	0.000406	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—CXCL8—urinary bladder cancer	2.85e-06	0.000406	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—CXCL8—urinary bladder cancer	2.82e-06	0.000402	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—KRAS—urinary bladder cancer	2.8e-06	0.000399	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—RHOA—urinary bladder cancer	2.73e-06	0.000389	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—IL2—urinary bladder cancer	2.73e-06	0.000389	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—IL2—urinary bladder cancer	2.72e-06	0.000388	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—TERT—urinary bladder cancer	2.72e-06	0.000387	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—TERT—urinary bladder cancer	2.71e-06	0.000386	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—IL2—urinary bladder cancer	2.69e-06	0.000384	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—TERT—urinary bladder cancer	2.68e-06	0.000382	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—ERBB2—urinary bladder cancer	2.64e-06	0.000376	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—PPARG—urinary bladder cancer	2.64e-06	0.000376	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—GSTP1—urinary bladder cancer	2.54e-06	0.000362	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—CREBBP—urinary bladder cancer	2.53e-06	0.000361	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—ERBB2—urinary bladder cancer	2.53e-06	0.00036	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—RRM2—urinary bladder cancer	2.51e-06	0.000358	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—CXCL8—urinary bladder cancer	2.5e-06	0.000356	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—FGFR3—urinary bladder cancer	2.5e-06	0.000355	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—FGFR3—urinary bladder cancer	2.49e-06	0.000354	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—HRAS—urinary bladder cancer	2.49e-06	0.000354	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—FGFR3—urinary bladder cancer	2.46e-06	0.000351	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—ESR1—urinary bladder cancer	2.42e-06	0.000345	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—ESR1—urinary bladder cancer	2.42e-06	0.000344	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—CXCL8—urinary bladder cancer	2.4e-06	0.000341	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	2.39e-06	0.000341	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—ESR1—urinary bladder cancer	2.39e-06	0.000341	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—IL2—urinary bladder cancer	2.39e-06	0.000341	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—HRAS—urinary bladder cancer	2.38e-06	0.000339	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—TYMS—urinary bladder cancer	2.36e-06	0.000336	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—NCOR1—urinary bladder cancer	2.33e-06	0.000332	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—GSTM1—urinary bladder cancer	2.33e-06	0.000332	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—CCND1—urinary bladder cancer	2.33e-06	0.000332	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	2.33e-06	0.000332	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—ENO2—urinary bladder cancer	2.33e-06	0.000332	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—IL2—urinary bladder cancer	2.29e-06	0.000326	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—MMP9—urinary bladder cancer	2.26e-06	0.000322	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	2.26e-06	0.000322	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—CDKN1A—urinary bladder cancer	2.25e-06	0.000321	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—PTEN—urinary bladder cancer	2.25e-06	0.00032	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—GPX1—urinary bladder cancer	2.23e-06	0.000318	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—CCND1—urinary bladder cancer	2.23e-06	0.000318	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—TYMS—urinary bladder cancer	2.22e-06	0.000317	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	2.2e-06	0.000313	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	2.2e-06	0.000313	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—ERCC2—urinary bladder cancer	2.19e-06	0.000313	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—MMP9—urinary bladder cancer	2.17e-06	0.000309	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—CDKN1A—urinary bladder cancer	2.16e-06	0.000308	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—PTEN—urinary bladder cancer	2.15e-06	0.000307	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—EP300—urinary bladder cancer	2.15e-06	0.000306	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CREBBP—urinary bladder cancer	2.12e-06	0.000303	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CREBBP—urinary bladder cancer	2.12e-06	0.000302	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—GPX1—urinary bladder cancer	2.11e-06	0.0003	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—IGF1—urinary bladder cancer	2.1e-06	0.000299	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CREBBP—urinary bladder cancer	2.1e-06	0.000299	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—IGF1—urinary bladder cancer	2.09e-06	0.000298	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—EGFR—urinary bladder cancer	2.09e-06	0.000297	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—SRC—urinary bladder cancer	2.09e-06	0.000297	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—EGFR—urinary bladder cancer	2.08e-06	0.000296	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—PTGS2—urinary bladder cancer	2.07e-06	0.000295	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—IGF1—urinary bladder cancer	2.07e-06	0.000295	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	2.07e-06	0.000295	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—MTHFR—urinary bladder cancer	2.06e-06	0.000294	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—EGFR—urinary bladder cancer	2.06e-06	0.000294	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—EP300—urinary bladder cancer	2.05e-06	0.000293	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—SRC—urinary bladder cancer	2e-06	0.000285	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—KRAS—urinary bladder cancer	1.97e-06	0.000281	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—KRAS—urinary bladder cancer	1.97e-06	0.00028	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—KRAS—urinary bladder cancer	1.95e-06	0.000277	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	1.94e-06	0.000277	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—RHOA—urinary bladder cancer	1.92e-06	0.000274	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—RHOA—urinary bladder cancer	1.92e-06	0.000273	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—RHOA—urinary bladder cancer	1.9e-06	0.00027	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.88e-06	0.000267	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—MYC—urinary bladder cancer	1.87e-06	0.000266	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—EGFR—urinary bladder cancer	1.83e-06	0.000261	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—PTEN—urinary bladder cancer	1.81e-06	0.000258	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—MYC—urinary bladder cancer	1.79e-06	0.000255	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—ERBB2—urinary bladder cancer	1.78e-06	0.000253	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—ERBB2—urinary bladder cancer	1.77e-06	0.000253	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—ERBB2—urinary bladder cancer	1.76e-06	0.00025	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—EGFR—urinary bladder cancer	1.75e-06	0.000249	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—KRAS—urinary bladder cancer	1.73e-06	0.000246	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—EP300—urinary bladder cancer	1.72e-06	0.000246	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CXCL8—urinary bladder cancer	1.69e-06	0.00024	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CXCL8—urinary bladder cancer	1.68e-06	0.00024	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—HRAS—urinary bladder cancer	1.68e-06	0.000239	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PPARG—urinary bladder cancer	1.67e-06	0.000238	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—HRAS—urinary bladder cancer	1.67e-06	0.000238	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CXCL8—urinary bladder cancer	1.67e-06	0.000237	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—HRAS—urinary bladder cancer	1.65e-06	0.000236	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—KRAS—urinary bladder cancer	1.65e-06	0.000236	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—IL2—urinary bladder cancer	1.61e-06	0.00023	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—IL2—urinary bladder cancer	1.61e-06	0.000229	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—CREBBP—urinary bladder cancer	1.61e-06	0.000229	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—IL2—urinary bladder cancer	1.59e-06	0.000227	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PPARG—urinary bladder cancer	1.58e-06	0.000225	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CCND1—urinary bladder cancer	1.57e-06	0.000224	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CCND1—urinary bladder cancer	1.57e-06	0.000223	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.56e-06	0.000223	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CCND1—urinary bladder cancer	1.55e-06	0.000221	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—TP53—urinary bladder cancer	1.54e-06	0.000219	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—MMP9—urinary bladder cancer	1.53e-06	0.000217	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—MMP9—urinary bladder cancer	1.52e-06	0.000217	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CDKN1A—urinary bladder cancer	1.52e-06	0.000217	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—PTEN—urinary bladder cancer	1.52e-06	0.000216	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CDKN1A—urinary bladder cancer	1.52e-06	0.000216	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	1.51e-06	0.000216	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—PTEN—urinary bladder cancer	1.51e-06	0.000215	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—MMP9—urinary bladder cancer	1.51e-06	0.000215	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CDKN1A—urinary bladder cancer	1.5e-06	0.000214	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—PTEN—urinary bladder cancer	1.5e-06	0.000213	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—TP53—urinary bladder cancer	1.47e-06	0.000209	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—HRAS—urinary bladder cancer	1.47e-06	0.000209	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.45e-06	0.000207	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—EP300—urinary bladder cancer	1.45e-06	0.000206	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—EP300—urinary bladder cancer	1.44e-06	0.000205	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.44e-06	0.000205	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.44e-06	0.000205	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—EP300—urinary bladder cancer	1.43e-06	0.000203	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—SRC—urinary bladder cancer	1.41e-06	0.0002	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—HRAS—urinary bladder cancer	1.41e-06	0.0002	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—SRC—urinary bladder cancer	1.4e-06	0.0002	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—SRC—urinary bladder cancer	1.39e-06	0.000198	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.38e-06	0.000196	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.35e-06	0.000193	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PTGS2—urinary bladder cancer	1.32e-06	0.000187	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.27e-06	0.000181	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—MYC—urinary bladder cancer	1.26e-06	0.00018	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—MYC—urinary bladder cancer	1.26e-06	0.000179	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—MYC—urinary bladder cancer	1.24e-06	0.000177	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	1.24e-06	0.000177	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—EGFR—urinary bladder cancer	1.23e-06	0.000176	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—EGFR—urinary bladder cancer	1.23e-06	0.000175	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—EGFR—urinary bladder cancer	1.22e-06	0.000173	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—KRAS—urinary bladder cancer	1.16e-06	0.000166	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—KRAS—urinary bladder cancer	1.16e-06	0.000165	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—KRAS—urinary bladder cancer	1.15e-06	0.000164	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PTEN—urinary bladder cancer	1.15e-06	0.000163	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—EP300—urinary bladder cancer	1.09e-06	0.000156	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PTEN—urinary bladder cancer	1.08e-06	0.000154	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—TP53—urinary bladder cancer	1.04e-06	0.000147	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—TP53—urinary bladder cancer	1.03e-06	0.000147	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—EP300—urinary bladder cancer	1.03e-06	0.000147	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PPARG—urinary bladder cancer	1.03e-06	0.000147	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—TP53—urinary bladder cancer	1.02e-06	0.000146	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—HRAS—urinary bladder cancer	9.9e-07	0.000141	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	9.9e-07	0.000141	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—HRAS—urinary bladder cancer	9.87e-07	0.000141	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—HRAS—urinary bladder cancer	9.77e-07	0.000139	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	8.11e-07	0.000115	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PTEN—urinary bladder cancer	7.07e-07	0.000101	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—EP300—urinary bladder cancer	6.74e-07	9.6e-05	CbGpPWpGaD
